170. Occipital horn syndrome Clinical trials / Disease details


Clinical trials : 2 Drugs : 4 - (DrugBank : 3) / Drug target genes : 9 - Drug target pathways : 14

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04977388
(ClinicalTrials.gov)
July 12, 20219/7/2021NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn SyndromePhase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical TrialMenkes Disease;Occipital Horn SyndromeDrug: Droxidopa;Other: PlaceboStephen G. Kaler, MDNULLRecruiting18 Years50 YearsAll6Phase 1/Phase 2United States
2NCT00811785
(ClinicalTrials.gov)
February 27, 200918/12/2008Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper DeficiencyMolecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper DeficiencyMenkes Disease;Occipital Horn Syndrome;Unexplained Copper DeficiencyDrug: Copper HistidineCyprium Therapeutics, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH)CompletedN/A80 YearsAll93Phase 3United States